<i>CYP19</i> Genetic Polymorphism Haplotype <i>AASA</i> Is Associated with a Poor Prognosis in Premenopausal Women with Lymph Node-Negative, Hormone Receptor-Positive Breast Cancer

<table>Overall treatment results for LN-negative, HR-positive premenopausal patients as a function of <i>CYP19</i> haplotype (<i>AASA</i> haplotype versus non-<i>AASA </i>haplotype) for (a) distant disease-free survival (DDFS), (b) disease-free survival (DFS), and (c) overall survival (OS).</table>

BioMed Research International

fig1

Figure 1

Figure 1: <i>CYP19</i> Genetic Polymorphism Haplotype <i>AASA</i> Is Associated with a Poor Prognosis in Premenopausal Women with Lymph Node-Negative, Hormone Receptor-Positive Breast Cancer 

Figure 1 | CYP19 Genetic Polymorphism Haplotype AASA Is Associated with a Poor Prognosis in Premenopausal Women with Lymph Node-Negative, Hormone Receptor-Positive Breast Cancer 